JUST as Nissan Philippines Inc. (NPI) prepared to launch the heavily updated Kicks e-Power this July, Japan has already moved on to an entirely new generation.

AMG has done a lot with the CLE to make it truly special, providing satisfaction to lovers of driving, style, opulence, and ...

Cumberland Pharmaceuticals Inc. , an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase 2 FIGHT DMD trial ...

Menstrual cycle phases influence heart autonomic regulation, showing HRV variations, yet muscle performance and mood states ...

Osteosarcopenia is a disorder characterized by bone loss and muscular atrophy (also known as osteoporosis and sarcopenia), and it is often seen in post-menopausal women. The musculoskeletal system is ...

Lightweight robot helps children with SMA stand independently, boosting muscle strength and mobility through resistance training.

The identification of HALO as SMN enhancer was highlighted in our previous FDA-approved drug screening (in the patent PCT/EP2022/087022 for its use in SMA referred as “compound 5”) 12, thus requiring ...

Duchenne muscular dystrophy (DMD) is caused by a mutation in the DMD gene that prevents dystrophin production, leading to progressive muscle weakness and early mobility challenges. The 2018 DMD ...

This study reveals abnormal iron accumulation in the muscles of patients with Facioscapulohumeral Muscular Dystrophy (FSHD) and in mice expressing muscle-specific DUX4 (DUX4-Tg mice). Contrary to ...

Translational proof-of-concept studies for gene therapeutics often match the payload gene sequence to the preclinical animal model as this avoids immune responses that could compromise drug efficacy.

With a $298 million series B round, Function Health has now hit unicorn status with a $2.5 billion valuation. (Arkadiusz Warguła/GettyImages) Function Health, a startup that offers lab testing and ...

The least-squares mean difference in the Hammersmith Functional Motor Scale-Expanded change from baseline at 12 months was 1.8 points for those 2 to 12 years receiving apitegromab vs placebo.